Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
BMJ Open. 2023 Jan 11;13(1):e063391. doi: 10.1136/bmjopen-2022-063391.
To describe the mental health of perinatal women in five European countries during the third pandemic wave and identify risk factors related to depressive and anxiety symptoms.
A cross-sectional, online survey-based study.
Belgium, Norway, Switzerland, the Netherlands and the UK, 10 June 2021-22 August 2021.
Pregnant and up to 3 months postpartum women, older than 18 years of age.
The Edinburgh Depression Scale (EDS) and the Generalised Anxiety Disorder scale (GAD-7) were used to assess mental health status. Univariate and multivariate generalised linear models were performed to identify factors associated with poor mental health.
5210 women participated (including 3411 pregnant and 1799 postpartum women). The prevalence of major depressive symptoms (EDS ≥13) was 16.1% in the pregnancy group and 17.0% in the postpartum . Moderate to severe generalised anxiety symptoms (GAD ≥10) were found among 17.3% of the pregnant and 17.7% of the postpartum women. Risk factors associated with poor mental health included having a pre-existing mental illness, a chronic somatic illness, having had COVID-19 or its symptoms, smoking, unplanned pregnancy and country of residence. Among COVID-19 restrictive measures specific to perinatal care, pregnant and postpartum women were most anxious about not having their partner present at the time of delivery, that their partner had to leave the hospital early and to be separated from their newborn after the delivery.
Approximately one in six pregnant or postpartum women reported major depression or anxiety symptoms during the third wave of the pandemic. These findings suggest a continued need to monitor depression and anxiety in pregnancy and postpartum populations throughout and in the wake of the pandemic. Tailored support and counselling are essential to reduce the burden of the pandemic on perinatal and infant mental health.
描述五个欧洲国家在第三次大流行期间围产期妇女的心理健康状况,并确定与抑郁和焦虑症状相关的风险因素。
横断面、基于在线调查的研究。
比利时、挪威、瑞士、荷兰和英国,2021 年 6 月 10 日至 2021 年 8 月 22 日。
18 岁以上的孕妇和产后 3 个月内的妇女。
使用爱丁堡抑郁量表(EDS)和广泛性焦虑障碍量表(GAD-7)评估心理健康状况。进行单变量和多变量广义线性模型分析,以确定与不良心理健康相关的因素。
共有 5210 名女性参与(包括 3411 名孕妇和 1799 名产后女性)。在妊娠组中,重度抑郁症状(EDS≥13)的患病率为 16.1%,在产后组中为 17.0%。17.3%的孕妇和 17.7%的产后妇女存在中度至重度广泛性焦虑症状(GAD≥10)。与不良心理健康相关的风险因素包括先前存在精神疾病、慢性躯体疾病、感染过 COVID-19 或出现过 COVID-19 症状、吸烟、非计划妊娠和居住地。在围产期保健的 COVID-19 特定限制措施中,孕妇和产后妇女最担心的是分娩时伴侣不在场、伴侣必须提前出院以及分娩后与新生儿分离。
大约六分之一的孕妇或产后妇女在第三次大流行期间报告有重度抑郁或焦虑症状。这些发现表明,在大流行期间及其后,仍需继续监测围产期人群的抑郁和焦虑情况。提供量身定制的支持和咨询至关重要,以减轻大流行对围产期和婴儿心理健康的负担。